Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 16/20 | 0.49 |
| ▸ | INSR | P06213 | 10/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6420350 | 0.94 | ITK (0.50) | ITKINSREGFR | |
| SCHEMBL6273767 | 0.89 | ITK (0.42) | ITKINSREGFR | |
| SCHEMBL6273966 | 0.86 | ITK (0.45) | ITKINSREGFRADORA2AHDAC6 | |
| SCHEMBL6276868 | 0.83 | ITK (0.39) | ITKINSREGFR | |
| SCHEMBL6420360 | 0.80 | ITK (0.47) | ITKINSREGFRADORA2A | |
| SCHEMBL6270096 | 0.80 | GRM2 (0.49) | ITKINSREGFR | |
| SCHEMBL6418924 | 0.79 | ITK (0.46) | ITKINSRHDAC6 | |
| SCHEMBL6420438 | 0.78 | ITK (0.55) | ITKINSR | |
| SCHEMBL6420992 | 0.78 | ITK (0.55) | ITKINSR | |
| SCHEMBL6274629 | 0.78 | ITK (0.55) | ITKINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050209284-A1 | Tec kinase inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | US | disclosed |
| WO-2005079791-A1 | THIOPHENE -2- CARBOXYLIC ACID - (1H - BENZIMIDAZOL - 2 YL) - AMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE TEC KINASE ITK (INTERLEUKIN -2- INDUCIBLE T CELL KINASE) FOR THE TREATMENT OF INFLAMMATION, IMMUNOLOGICAL AND ALLERGIC DISORDERS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209284-A1 | Tec kinase inhibitors | TEC, ITK, TXK | ITK 2/4885INSR 910/4885EGFR 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.